Danvatirsen Plus Venetoclax
A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 24 patients (estimated)
- Sponsors
- Montefiore Medical Center
- Collaborators
- MD Anderson Cancer Center
- Tags
- Antisense Oligonucleotide (ASO), BCL-2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1749
- NCT Identifier
- NCT05986240
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.